Health Care & Life Sciences » Biotechnology | Palatin Technologies Inc.

Palatin Technologies Inc.

Palatin Technologies Inc.
Stock Exchange NYSE
EPS
$0.02
Market Cap
$222.02 M
Shares Outstanding
215.56 M
Public Float
191.81 M
Palatin Technologies Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
198.68 M
Public Float
196.67 M

Profile

Address
Cedar Brook Corporate Center
Cranbury New Jersey 08512
United States
Employees -
Website http://www.palatin.com
Updated 07/08/2019
Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress.

Financials

View All

Carl Spana
President, Chief Executive Officer & Director
John K. A. Prendergast
Chairman